Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

varlitinib (ASLAN001)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

ASLAN Pharma, Blade Entertaintment, Pfizer

Drug class:

EGFR inhibitor, HER2 inhibitor, HER4 inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

trastuzumab (407)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

zenocutuzumab-zbco (16)

trastuzumab-dttb (11)

zanidatamab-hrii (10)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

›

HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	ASLAN001 Sensitive: C2 – Inclusion Criteria ASLAN001 Sensitive : C2	ASLAN001 Sensitive: C2 – Inclusion Criteria ASLAN001 Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ASLAN001 Sensitive: C2 – Inclusion Criteria ASLAN001 Sensitive : C2	ASLAN001 Sensitive: C2 – Inclusion Criteria ASLAN001 Sensitive : C2
EGFR overexpression	Gastric Cancer	EGFR overexpression	Gastric Cancer	ASLAN001 Sensitive: C3 – Early Trials ASLAN001 Sensitive : C3	ASLAN001 Sensitive: C3 – Early Trials ASLAN001 Sensitive : C3
EGFR expression + HER-2 expression	Gastric Cancer	EGFR expression + HER-2 expression	Gastric Cancer	ASLAN001 Sensitive: C3 – Early Trials ASLAN001 Sensitive : C3	ASLAN001 Sensitive: C3 – Early Trials ASLAN001 Sensitive : C3
EGFR overexpression + HER-2 overexpression	Cholangiocarcinoma	EGFR overexpression + HER-2 overexpression	Cholangiocarcinoma	ASLAN001 Sensitive: D – Preclinical ASLAN001 Sensitive : D	ASLAN001 Sensitive: D – Preclinical ASLAN001 Sensitive : D
EGFR overexpression + HER-2 overexpression	Cholangiocarcinoma	EGFR overexpression + HER-2 overexpression	Cholangiocarcinoma	AN2025 + ASLAN001 Sensitive: D – Preclinical AN2025 + ASLAN001 Sensitive : D	AN2025 + ASLAN001 Sensitive: D – Preclinical AN2025 + ASLAN001 Sensitive : D